JPMorgan downgraded Rapt Therapeutics (RAPT) to Underweight from Neutral. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on RAPT: Rapt Therapeutics model under review at Stifel after zelnecirnon discontinued Rapt Therapeutics terminates zelnecirnon program following clinical hold